TrkA
TrkA (tropomyosin receptor kinase A; encoded by NTRK1) is a high-affinity receptor tyrosine kinase for nerve growth factor (NGF) that regulates neuronal survival, differentiation, and sensory neuron function through ligand-induced receptor dimerization and autophosphorylation[1][2]. Mechanistically, NGF-TrkA signaling activates major downstream pathways including RAS/MAPK, PI3K/AKT, and PLCγ, thereby controlling transcriptional programs that support neuronal growth, maintenance, and synaptic function[1][2][3]. Through these signaling cascades, TrkA plays a central role in the development and maintenance of nociceptive neurons and contributes to neurotrophin-dependent cellular responses in the peripheral and central nervous systems[1][2]. In disease contexts, dysregulation of NGF/TrkA signaling has been implicated in chronic pain disorders and neurodegenerative conditions, including experimental models of Alzheimer's disease in which impaired TrkA signaling is associated with cholinergic neuronal dysfunction and synaptic deficits[3][4][5]. Compared with related neurotrophin receptors, TrkA is distinguished by its preferential activation by NGF, whereas TrkB primarily responds to BDNF and NT-4/5 and TrkC is activated predominantly by NT-3, enabling receptor-specific biological outcomes[6]. For experimental applications, both agonists and antagonists targeting the NGF-TrkA axis have been widely utilized to investigate neurotrophic signaling, neuronal survival mechanisms, and pain-related pathways, making TrkA an important molecular target in translational neuroscience research[4][5].
References:
- [1]. Norman BH, et al. Targeting the Nerve Growth Factor (NGF) Pathway in Drug Discovery. Potential Applications to New Therapies for Chronic Pain. J Med Chem. 2017 Jan 12;60(1):66-88. [Content Brief]
- [2]. Indo Y. NTRK1 Congenital Insensitivity to Pain with Anhidrosis. 2008 Aug 5 [updated 2020 Apr 30]. In: Adam MP, et al. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026. PMID: 20301726. [Content Brief]
- [3]. Latina V, et al. Impaired NGF/TrkA Signaling Causes Early AD-Linked Presynaptic Dysfunction in Cholinergic Primary Neurons. Front Cell Neurosci. 2017 Mar 15;11:68. doi: 10.3389/fncel.2017.00068. PMID: 28360840; PMCID: PMC5350152. [Content Brief]
- [4]. Baño V, et al. Characterization and Structural Performance in Bending of CLT Panels Made from Small-Diameter Logs of Loblolly/Slash Pine. Materials (Basel). 2018 Nov 30;11(12):2436. [Content Brief]
- [5]. Mantyh PW, et al. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology. 2011 Jul;115(1):189-204. [Content Brief]
- [6]. Clinical Guidelines on the Identification, et al. National Institutes of Health. Obes Res. 1998 Sep;6 Suppl 2:51S-209S. Erratum in: Obes Res 1998 Nov;6(6):464. PMID: 9813653. [Content Brief]
-
TrkA Related Products (77)
Related Products (77)
-
Antibodies (4)
-
KRC-108
0 ImagesCat. No.: HY-123237CAS No.: 1146944-35-5KRC-108, an aminopyridine, is an orally active multiple kinase inhibitor with IC50s of 80 nM, 23 nM, 3 nM, 70 nM, 30 nM, 39 nM for c-Met, c-Met M1250T, c-Met Y1230D, Ron, Flt3 and TrkA, respectively. KRC-108 induces cell cycle arrest, apoptotic cell death, and autophagy. KRC-108 exhibits anti-tumor activity in vivo in HT29 colorectal cancer, NCI-H441 lung cancer xenograft models in athymic BALB/c nu/nu mice.
-
DZX19
0 ImagesCat. No.: HY-181871DZX19 (Compound C02) is an orally active, selective TRK inhibitor with a TRKA IC50 value of 1.32 nM, a TRKB IC50 of 2.28 nM, and a TRKC IC50 of 4.05 nM. DZX19 inhibits the kinase activities of wild-type TRKA, TRKA mutants (G595R, F589L, G667C), wild-type TRKB, and wild-type TRKC, and suppresses the phosphorylation of TRKA as well as its downstream AKT and ERK signaling pathways. DZX19 induces apoptosis. DZX19 inhibits tumor growth in a colorectal cancer xenograft mouse model. DZX19 is applicable for the research of colorectal cancer.
-
Trk-IN-7
0 ImagesCat. No.: HY-143557CAS No.: 2383011-61-6
-
TRK/ALK-IN-1
0 ImagesCat. No.: HY-144732CAS No.: 3052405-64-5TRK/ALK-IN-1 (compound 21) is a potent and dual inhibitor of TRK and ALK. TRK/ALK-IN-1 in the enzymatic assays is in good accordance with anti-proliferative activity with IC50 values of 2.2, 9.3 and 38 nM towards TRKA, ALKWT and ALKL1196M, respectively. TRK/ALK-IN-1 has the potential for the research of cancer diseases.
-
Trk-IN-20
0 ImagesCat. No.: HY-150561CAS No.: 2460924-63-2
-
TRK-IN-23
0 ImagesCat. No.: HY-149965CAS No.: 2924344-29-4
-
GR2-128
0 ImagesCat. No.: HY-184396GR2-128 is a dual inhibitor targeting MLK3 and NAMPT with IC50 values of 84 nM and 14 nM, respectively. GR2-128 inhibits downstream JNK/c‑Jun signaling and reduces NAD+ levels. GR2-128 exhibits antiproliferative and pro-apoptotic activities in triple-negative breast cancer cells without significant toxicity to normal cells. GR2-128 suppresses tumor growth, reduces macrophage and neutrophil infiltration, and increases tumor T-cell markers in a syngeneic mouse model, and can be used for triple-negative breast cancer research.
-
ZW-18-116
0 ImagesCat. No.: HY-180550ZW-18-116 (compound 9) is a dual-target PROTAC degrader for the oncoproteins TRKA and RET. ZW-18-116 induces the degradation of oncoproteins TRKA and RET by recruiting the CRBN E3 ligase. ZW-18-116 exhibits potent anti-proliferative activity in various cancer cell lines harboring RET or TRKA fusions. ZW-18-116 can be used for RET or TRKA-derived cancer research, such as thyroid, lung, and colon cancers.
-
TIY-7
0 ImagesCat. No.: HY-146755CAS No.: 2846435-83-2TIY-7 is a selective and orally active tropomyosin receptor kinase (TRK) inhibitor. TIY-7 shows enzyme inhibitory activity with IC50s of 2.9, 1.1, 0.7, 0.8, 0.8, 0.2 nM for TRKA, TRKAG595R, TRKAG667C, TRKAF589L, TRKCG623R, TRKCG696A, respectively. TIY-7 shows anti-tumor potency in mouse xenograft model.
-
Protein kinase inhibitor 5 sulfate hydrate
0 ImagesCat. No.: HY-153745AProtein kinase inhibitor 5 sulfate hydrate is a potent TRK-A inhibitor with an IC50 value of 1.8 nM. Protein kinase inhibitor 5 sulfate hydrate inhibits cell viability.
-
ZW-6-052
0 ImagesCat. No.: HY-180551ZW-6-052 (compound 20), the derivative of ZW-18-116 (HY-180550), is a dual-target PROTAC degrader for the oncoproteins TRKA and RET. ZW-6-052 induces degradation of TMP3-TRKA in KM12 mouse xenograft models. ZW-6-052 can be used for RET or TRKA-derived cancer research, such as thyroid, lung, and colon cancers.
-
Multi-kinase-IN-7
0 ImagesCat. No.: HY-178142Multi-kinase-IN-7 is a multikinase inhibitor with IC50s of 2.19, 2.95, 3.59 and 9.31 μM against EGFR, VEGFR2, TrKA and CDK2, respectively. Multi-kinase-IN-7 shows moderate and weaker activity against FAK, AKT1, GSK3β and CDK5 with IC50 values of 6.3, 9.2, 11.7 and 23.4 μM, respectively. Multi-kinase-IN-7 displays broad spectrum antiproliferative potential against NCI cancer cell lines. Multi-kinase-IN-7 induces cell cycle arrest, apoptosis and necrosis. Multi-kinase-IN-7 Inhibitor can be used for the study of breast cancer.
-
Pegcantratinib
0 ImagesCat. No.: HY-19704CAS No.: 1233363-33-1Synonyms: CT327; SNA-120
-
PF-07245303
0 ImagesCat. No.: HY-182335CAS No.: 2655556-75-3PF-07245303 is a ITK/TRK inhibitor. PF-07245303 reduces the production of inflammatory cytokines such as IL-4 and IFNγ, and inhibits the phosphorylation of PLCγ1. PF-07245303 inhibits nerve growth factor-induced basophil activation and the phosphorylation of TRKA. PF-07245303 reduces oxazolone-induced ear swelling in mouse ear tissues. PF-07245303 is applicable to research related to atopic dermatitis.
-
Protein kinase inhibitor 5
0 ImagesCat. No.: HY-153745CAS No.: 2278204-94-5Protein kinase inhibitor 5 is a potent TRK-A inhibitor with an IC50 value of 1.8 nM. Protein kinase inhibitor 5 inhibits cell viability.
-
Trk-IN-11
0 ImagesCat. No.: HY-144424CAS No.: 2700265-62-7
